TheraCryf PLC
Company Profile
Business description
TheraCryf PLC is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of unmet medical need within central nervous system (CNS) disorders. The Group's main programme is a novel, benchmark orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol, and other substance use disorders. It also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy, and narcolepsy. The Group also has an oncology programme in glioblastoma with SFX-01. It operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
9
Stocks News & Analysis
stocks
Undervalued wide moat share may be overlooked
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,160.30 | 13.70 | -0.15% |
| CAC 40 | 8,301.85 | 32.65 | -0.39% |
| DAX 40 | 25,970.11 | 288.00 | -1.10% |
| Dow JONES (US) | 52,766.88 | 419.02 | -0.79% |
| FTSE 100 | 10,789.28 | 34.98 | -0.32% |
| HKSE | 25,258.10 | 71.63 | -0.28% |
| NASDAQ | 26,099.77 | 271.12 | -1.03% |
| Nikkei 225 | 64,325.64 | 1,889.70 | -2.85% |
| NZX 50 Index | 13,930.57 | 143.67 | 1.04% |
| S&P 500 | 7,631.47 | 54.67 | -0.71% |
| S&P/ASX 200 | 8,978.40 | 1.80 | -0.02% |
| SSE Composite Index | 3,946.37 | 33.52 | -0.84% |